Women with breast cancer aged 35 or younger were more likely than older women to achieve a pathological complete response after neoadjuvant chemotherapy, according to data presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held December 4-8 in san Antonio, Texas.

“Young women with breast cancer are rare, and some data indicate that their prognosis is worse than it is for older women,” said…

Research over the last several decades has helped deliver improved therapeutic options for patients suffering from leukemia, a condition that still remains lethal. New options to help diagnose the condition earlier and new therapies that will extend patients’ lives are needed. Research from a number of major studies addressing important updates on the diagnosis and treatment of leukemia were presented at the 53rd Annual Meeting of…

Researchers are studying to see if they can determine sooner whether the drug doxorubin (Adriamycin®/Doxil®) – often called the red stuff by patients because of its ruby red color – might cause long-term damage to breast…

A randomized Phase III trial conducted by researchers of the University of Vienna and St. Anna Children’s Cancer Research Institute Vienna, Austria, showed that children with high-risk neuroblastoma, the most common extracranial solid tumor in infancy, had better event-free and overall survival with a combination of the myeloablative…

A prospective study, MUNICON II, has shown that detecting early metabolic response to chemotherapy by positron emission tomography (PET) imaging prior to surgery is useful in determining a patient’s prognosis for locally advanced adenocarcinoma of the esophagogastric junction. Researchers also found that those who did not respond to chemotherapy did not benefit from additional radiation. The study results were presented during the eighth annual Gastrointestinal Cancers Symposium,…

Final phase II data for the investigational drug iniparib (BSI-201) demonstrates significant clinical benefit in women with metastatic triple negative breast cancer (mTNBC) when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.[1] [2]



Triple-negative breast cancer (TNBC) is an aggressive cancer subtype associated with defects in DNA repair mechanism, including BRCA1 dysfunction. This makes this cancer a rational…

Research led by St. Jude Children's Research Hospital investigators will likely impact how acute lymphoblastic leukemia is treated in young adults and shows older adolescent age does not dictate worse outcomes against the most common childhood cancer. More effective risk-adjusted chemotherapy and sophisticated patient monitoring helped push cure rates to nearly 88% for older adolescents enrolled in a St. Jude Children's…

Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.



Gunter von Minckwitz, M.D., Ph.D., managing director of the German Breast Group, and colleagues are conducting final analyses on efficacy data from this study, which will detail the early treatment of more than 1,900…